Ensoma
Stefano Stella brings significant expertise in gene editing, structural biology, protein engineering and nucleic acid/protein interactions, ranging from ribosomes to TALENs and meganucleases to CRISPR systems. Prior to joining Ensoma, Stefano was the co-founder, chief technology officer, and director at Twelve Bio ApS and Associate Professor at the University of Copenhagen, Novo Nordisk Foundation Center for Protein Research, where he focused on understanding the atomic details of CRISPR-Cas12a cleavage activities. Prior to the University of Copenhagen, Stefano held research positions at the Spanish National Cancer Research Centre and The Institute of Genetics and Molecular and Cellular Biology following completion of his postdoctoral training at University of California, Los Angeles.
Stefano holds a Master’s Degree in Biology and Biochemistry from Università della Calabria and a Ph.D. in Molecular Biology and Genetics from University of Camerino.
Ensoma
1 followers
Ensoma believes every person, no matter where they are, should have access to innovative technologies that are changing the way we treat disease. Harnessing the power of their Engenious™ vectors, their therapies can be delivered in a simple, single injection.